Paul Balderes
Eli Lilly and Company
35 Papers
271 Citations
Paul Balderes is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Protein kinase B & Receptor tyrosine kinase. The author has an hindex of 17, co-authored 31 publications. Previous affiliations of Paul Balderes include Protein Sciences & ImmunoGen, Inc..
Chat about Author
Papers
A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity
Dan Lu,Haifan Zhang,Henry Koo,James R. Tonra,Paul Balderes,Marie Prewett,Eric Corcoran,Venkata R.M. Mangalampalli,Rajiv Bassi,Deborah Anselma,Dipa Patel,Xiaoqiang Kang,Dale L. Ludwig,Daniel J. Hicklin,Peter Bohlen,Larry Witte,Zhenping Zhu +16 more
TL;DR: A recombinant human IgG-like bispecific antibody, a Di-diabody, produced using the variable regions from two antagonistic antibodies that binds to both EGFR and IGFR and effectively blocked both EGF- and IGF-stimulated receptor activation and tumor cell proliferation.
310
Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody
Dan Lu,Haifan Zhang,Dale L. Ludwig,Anita Persaud,Xenia Jimenez,Douglas Burtrum,Paul Balderes,Meilin Liu,Peter Bohlen,Larry Witte,Zhenping Zhu +10 more
TL;DR: The first time use of a recombinant BsAb for targeting two tumor-associated molecules on either a single or adjacent tumor cells for enhanced antitumor activity is described, underscore the benefits of simultaneous targeting multiple growth factor receptor pathways for more efficacious cancer treatment.
217
Therapeutic Implications of a Human Neutralizing Antibody to the Macrophage-Stimulating Protein Receptor Tyrosine Kinase (RON), a c-MET Family Member
Jennifer O'Toole,Karen E. Rabenau,Kerri Burns,Dan Lu,Venkat Mangalampalli,Paul Balderes,Nicole Covino,Rajiv Bassi,Marie Prewett,Kimberly J. Gottfredsen,Megan N. Thobe,Yuan Cheng,Yiwen Li,Daniel J. Hicklin,Zhenping Zhu,Susan E. Waltz,Michael J. Hayman,Dale L. Ludwig,Daniel S. Pereira +18 more
TL;DR: This is the first demonstration that a RON antagonist and specifically an inhibitory antibody of RON negatively affects tumorigenesis, and highlights the potential therapeutic usefulness of Ron activity inhibition in human cancers.
158
Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer
Yan Wu,Zhaojing Zhong,James Huber,Rajiv Bassi,Bridget Finnerty,Erik Corcoran,Huiling Li,Elizabeth Navarro,Paul Balderes,Xenia Jimenez,Henry Koo,Venkata R.M. Mangalampalli,Dale L. Ludwig,James R. Tonra,Daniel J. Hicklin +14 more
TL;DR: IMC-18F1 anti-VEGFR-1 has potential to provide clinical benefit to cancer patients and was evaluated in human breast cancer xenograft models and enhanced the antitumor efficacy of cytotoxic agents commonly used to treat breast cancer.
147
Di-diabody: a novel tetravalent bispecific antibody molecule by design.
Dan Lu,Xenia Jimenez,Haifan Zhang,Amanda Atkins,Laura Brennan,Paul Balderes,Peter Bohlen,Larry Witte,Zhenping Zhu +8 more
TL;DR: Compared to the bispecific/divalent diabody, the tetravalent di-diabody binds more efficiently to both of its target antigens and is more efficacious in blocking ligand binding to the receptors.
139